Trial · NCT02906566
Retinol on Human Skin Aging in East Asian Descent
NCT02906566, Phase 4, Completed, Stanford University; results first posted 2019-04-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Retinol on Human Skin Aging in East Asian Descent. Trials, record NCT02906566. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02906566
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Retinol on Human Skin Aging in East Asian Descent
- NCT number
- NCT02906566
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 110 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Intrinsic Aging of Skin
- Interventions
- Retinol, Placebo
- First posted
- 2016-09-20
- Last updated
- 2019-04-16
- Results first posted
- 2019-04-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) | Week 12 | Differences in transcript levels are reported as the number that were upregulated or downregulated in the participant's retinol-treated arm versus their placebo-treated arm. |
| Primary | Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Younger Group Versus Older Group as Baseline) | Week 1 | Differences in transcript levels are reported as the number of genes that were upregulated or downregulated in the Younger Group participant tissue samples, as compared to a baseline provided by tissue samples collected from the Older Group (prior to their treatment). |
| Secondary | Transepidermal Water Loss | Baseline; Week 12 | Transepidermal Water Loss of arm skin was measured in units of grams/hours/meters squared. |
| Secondary | Severity of Arm Skin Wrinkling | Baseline; Week 12 | Wrinkling was assessed by the investigator using a 10-point Likert scale (range 0 to 9, lower scores correspond to less wrinkling). |
| Secondary | Elasticity on Arm Skin | Baseline; week 12 | Elasticity was assessed using cutometry (R2 curve) as millimeters per second |
| Secondary | Count of Participants With Skin and Subcutaneous Adverse Events as a Measure of Type and Severity of Adverse Events | Baseline through week 12 | Skin and subcutaneous adverse events were assessed for this outcome and documented and scored according to CTCAE version 4.03. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) | Week 12 | Participants in the Young Group Ages 18-25 attended a single study visit at week 1 to provide tissue samples for comparison purposes, and are not included in this analysis. | genes | NUMBER |
| SECONDARY | Transepidermal Water Loss | Baseline; Week 12 | Participants in the Young Group Ages 18-25 attended a single study visit at week 1 to provide tissue samples for comparison purposes, and are not included in this analysis. | g/h/m^2 | MEAN |
| SECONDARY | Severity of Arm Skin Wrinkling | Baseline; Week 12 | Participants in the Young Group Ages 18-25 attended a single study visit at week 1 to provide tissue samples for comparison purposes, and are not included in this analysis. | units on a scale | MEAN |
| SECONDARY | Elasticity on Arm Skin | Baseline; week 12 | Participants in the Young Group Ages 18-25 attended a single study visit at week 1 to provide tissue samples for comparison purposes, and are not included in this analysis. | millimeters per second | MEAN |
| SECONDARY | Count of Participants With Skin and Subcutaneous Adverse Events as a Measure of Type and Severity of Adverse Events | Baseline through week 12 | Participants in the Young Group Ages 18-25 attended a single study visit at week 1 to provide tissue samples for comparison purposes, and are not included in this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Younger Group Versus Older Group as Baseline) | Week 1 | Only the participants in Younger Group (ages 18-25) are included in the analysis, since a comparison of the baseline data for the Older Group (ages 55-75) against itself is not clinically meaningful. | genes | NUMBER |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) | Older Group Ages 55-75 | Upregulated | 23 | genes | |
| Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) | Older Group Ages 55-75 | Downregulated | 21 | genes | |
| Transepidermal Water Loss | Retinol Treated Arm | Baseline | 17.1 | Standard Deviation 10.2 | g/h/m^2 |
| Transepidermal Water Loss | Placebo Treated Arm | Baseline | 16.2 | Standard Deviation 11.7 | g/h/m^2 |
| Transepidermal Water Loss | Retinol Treated Arm | Week 12 | 9.4 | Standard Deviation 6.7 | g/h/m^2 |
| Transepidermal Water Loss | Placebo Treated Arm | Week 12 | 10.2 | Standard Deviation 6.1 | g/h/m^2 |
| Severity of Arm Skin Wrinkling | Retinol Treated Arm | Baseline | 5.15 | Standard Deviation 1.96 | units on a scale |
| Severity of Arm Skin Wrinkling | Placebo Treated Arm | Baseline | 5.5 | Standard Deviation 1.59 | units on a scale |
| Severity of Arm Skin Wrinkling | Retinol Treated Arm | Week 12 | 4.85 | Standard Deviation 1.79 | units on a scale |
| Severity of Arm Skin Wrinkling | Placebo Treated Arm | Week 12 | 5.175 | Standard Deviation 1.28 | units on a scale |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Older Group Ages 55-75 | 24 | 48 |
| Overall Study | STARTED | Young Group Ages 18-25 | 10 | 10 |
| Overall Study | COMPLETED | Older Group Ages 55-75 | 21 | 42 |
| Overall Study | COMPLETED | Young Group Ages 18-25 | 10 | 10 |
| Overall Study | NOT COMPLETED | Older Group Ages 55-75 | 3 | 6 |
| Overall Study | NOT COMPLETED | Young Group Ages 18-25 | 0 | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory infection | Infections and infestations | Older Group Ages 55-75 | 3 | 24 | 4 |
| other | Upper respiratory infection | Infections and infestations | Young Group Ages 18-25 | 0 | 10 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Older Group Ages 55-75 | 2 | 24 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Young Group Ages 18-25 | 0 | 10 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Older Group Ages 55-75 | 0 | 24 |
| Total, all-cause mortality | Young Group Ages 18-25 | 0 | 10 |
| Total, other adverse events | Older Group Ages 55-75 | 4 | 24 |
| Total, other adverse events | Young Group Ages 18-25 | 0 | 10 |
| Total, serious adverse events | Older Group Ages 55-75 | 0 | 24 |
| Total, serious adverse events | Young Group Ages 18-25 | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Older Group Ages 55-75 vs Young Group Ages 18-25: deaths from any cause | Trial comparisons |
| Older Group Ages 55-75 vs Young Group Ages 18-25: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02906566
GET https://conductscience.org/api/trials/v1/NCT02906566/registered